A further use may be the inclusion of EEG/MEG recordings in clinical trials to track the effect of novel therapeutic strategies in DS, such as the green tea polyphenol and specific DYRK1A inhibitor epigallocatechin-3-gallate (De la Torre et al., 2014; Stagni et al., 2017) Importantly, EEG and LFP recordings in mice will provide valuable information of oscillatory activity regarding aneuploidy mimicking DS, as well as the underlying circuit impairment that explain the observed emerging alterations. The gene discussed is DYRK1A; the disease is Dravet syndrome.